0 0 0 0 0 0 0.0182435299109036 0.0203648705982181
Sign Up Today X
Thanks for submitting the form.
Stockreport

Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]

Evolus, Inc. (EOLS)  More Company Research Source: Seeking Alpha
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
CEO David Moatazedi described Evolus' focus on a "performance beauty strategy" centered around a cash-pay aesthetic model, emphasizing differentiation through partnerships and loyalty programs. Moatazedi highlighted the launch of Evolux, a program that rewards clinics with co-branded Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights Evolus expects 2026 revenues of $327M-$337M (10%-13% growth) and full-year profitability with a low to mid single-digit adjusted EBITDA margin. Evolus is broadening adoption of Evolysse, launching Estyme in Europe, expanding loyalty and rebate programs, and targeting FDA approval of Evolysse Sculpt to strengthen its brand and market share. Key risks include tariff exposure on French imports, two major competitor toxin launches, persistent filler market weakness, and clinic inventories that have not fully recovered. More T [Read more]
IMPACT SNAPSHOT EVENT TIME: EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
EOLS alerts
from News Quantified
EOLS
NEWS
EOLS
Earnings
EOLS
Analyst Actions
EOLS
SEC Filings
Stockreport

Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]

Evolus, Inc.  (EOLS) 
More Company Research Source: Seeking Alpha
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
CEO David Moatazedi described Evolus' focus on a "performance beauty strategy" centered around a cash-pay aesthetic model, emphasizing differentiation through partnerships and loyalty programs. Moatazedi highlighted the launch of Evolux, a program that rewards clinics with co-branded Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights Evolus expects 2026 revenues of $327M-$337M (10%-13% growth) and full-year profitability with a low to mid single-digit adjusted EBITDA margin. Evolus is broadening adoption of Evolysse, launching Estyme in Europe, expanding loyalty and rebate programs, and targeting FDA approval of Evolysse Sculpt to strengthen its brand and market share. Key risks include tariff exposure on French imports, two major competitor toxin launches, persistent filler market weakness, and clinic inventories that have not fully recovered. More T [Read more]
IMPACT SNAPSHOT
EVENT TIME:
EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS